跳至主要内容
临床试验/NCT01466452
NCT01466452Unknown2 期

Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing Coronary Artery Bypass Graft and/or Aortic Valve Surgery

Centro Cardiologico Monzino1 个研究点 分布在 1 个国家目标入组 99 人开始时间: 2011年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
发起方
入组人数
99
试验地点
1
主要终点
change in the levels of TXB2 in serum at 12 and 24 hours after administration of aspirin

研究概览

简要总结

This study is a randomized open label study that implies the administration of asprin according to three different regimens.

The aims of the study are:

  • to establish whether coronary artery bypass surgery and / or aortic valve replacement surgery with bioprostheses is associated with changes in the rate of platelet regeneration that can reduce the effectiveness of aspirin administered at a dose of 100mg/die in terms of inhibition of platelet biosynthesis of thromboxane A2.
  • to determine whether these patients need a different (shorter) interval of administration in order to completely and permanently inhibit the platelet COX-1.

The endpoints of this study are:

  • To evaluate the changes in the levels of TXB2 and 12-HETE in serum at 12 and 24 hours after administration of aspirin and the changes in the levels of 11-dehydro TXB2 urinary 8-iso-PGF2 alpha urinary, 2-3 dinor-6-chetoPGF1 alpha, Verify-NOW Aspirin, platelets crosslinked at 12 and 24 hours after administration of aspirin

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
None

入排标准

年龄范围
55 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • informed consent of the study signed
  • coronary artery bypass graft and / or aortic valve replacement surgery with bioprostheses
  • age between 55 and 80
  • ejection fraction > 30%.

排除标准

  • excessive bleeding (> 1000mL / 6 h) or the need of re operation for bleeding
  • perioperative myocardial infarction
  • stroke or renal failure requiring dialysis and need waiting for post-operative anticoagulation
  • patients undergoing coronary artery bypass grafting procedure as a consequence of failed percutaneous coronary intervention
  • patients undergoing off-pump coronary artery bypass graft
  • overt kidney or liver disease
  • therapies that influence the coagulation
  • fertile women

研究组 & 干预措施

Aspirin 100

Active Comparator

干预措施: Aspirin (Drug)

Aspirin 200

Active Comparator

干预措施: Aspirin (Drug)

Aspirin 100 x 2

Active Comparator

干预措施: Aspirin (Drug)

结局指标

主要结局

change in the levels of TXB2 in serum at 12 and 24 hours after administration of aspirin

时间窗: one year

change in the levels of 12-HETE in serum at 12 and 24 hours after administration of aspirin

时间窗: one year

次要结局

  • change in the levels of 11-dehydro TXB2 urinary at 12 and 24 hours after administration of aspirin(one year)
  • change in the levels of 8-iso-PGF2 alpha urinary at 12 and 24 hours after administration of aspirin(one year)
  • change in the levels of 2-3 dinor-6-chetoPGF1 alpha at 12 and 24 hours after administration of aspirin(one year)
  • change in the levels of Verify-NOW Aspirin, platelets crosslinked at 12 and 24 hours after administration of aspirin(one year)

研究者

发起方
Centro Cardiologico Monzino
申办方类型
Other
责任方
Principal Investigator
主要研究者

Alessandro Parolari

Assistant Professor of Cardiac Surgery

Centro Cardiologico Monzino

研究点 (1)

Loading locations...

相似试验